Shares of Liquidia (LQDA) are down $4.22, or 23%, to $13.80 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target raised to $32 from $25 at Needham
- Liquidia Advances with YUTREPIA After Court Ruling
- Liquidia schedules first commercial shipment of YUTREPIA
- Liquidia Technologies: Strong Market Position and Growth Potential Amid Legal Clarity and Strategic Advancements
- Legal Victory and Promising Clinical Profile Boost Liquidia Technologies’ Market Prospects